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anti-tumor activity. We hypothesized that partial depletion of 
CD8 cells might have a similar effect as primary GVHD prophy- 
laxis after alIo-PBSCT. We report a series of 25 patients (pts) 
(median age 47 yrs, 17M/8F) with hematologic malignancies (13 
AML, 4 NHL, 3 ALL, 3 MDS, 1 CML, 1 CLL) who underwent 
PBSCT utilizing HLA matched sibling donors. Pts received 
cyclophophamide and fractionated TBI (1400 cGy). Stem ceils 
were depleted of CDS+CD3+ T ceils with antibody coated high 
density microparticles (CD8-HDM, Biotransplant, Charlestown, 
MA). 20/25 were transplanted for advanced isease. GVHD pro- 
phylaxis consisted of tacrolimus (0.02mg/kg 1VCI daily) alone 
without methotrexate. Donors were mobilized with filgastrim (10 
mcg/kg/d x 5d) prior to stem cell collection. The median number 
of CD34+ cells infused was 5.9 x 10e6/kg (range, 2.1-22.1 x 
10e6/kg), 80% recovery. The number of CD3+CD4+ cells/kg 
infused was 5.3 x 10e7/kg (range, 1.8-9.0 x 10e7/kg) while the 
number of CD3+CD8+ cells was 1.9 x 10e5/kg (range, 0.1-5.2 x 
10eS/kg), >99% depletion. All patients engrafted. An absolute 
neutrophil count of 500/1 was achieved on Day +10 (range, 9-12). 
Sustained platelet counts of 20, 00W1 were attained on Day +14 
(range, 8-42). Chilnerism studies revealed 98-100% donor cells in 
17/17 pts tested. At 3 mouths, CD4+ T cells in peripheral blood 
outnumber CD8 + T cells. The CD4/CD8 ratio was 2.5 (range 
0.8-11.9). Most of the CD4+ cells were CD45RO+ while the 
majority of CD8 cells were CD45RA+. Grades 2-4 acute GVIID 
occurred in 11/25 patients (44%). Two patients have limited 
chronic GVItD. With a median follow-up of 270 days (range, 
123-376), 20/25 patients (80%) are alive, NED. There have been 
4 transplant related deaths (1 pneumonitis, 1 hepatic veno-occlu- 
sive disease, I Listeria meningitis, 1 GVHD) and 1 relapse. Our 
results suggest hat depletion of CDS+ T cells from mobilized 
blood with the CD8-HDM device does not hinder hematopoietic 
recove W after allo-PBSCT. The incidence of acute GVttD was 
less than that reported in pts receiving a calcineurin inhibitor 
aIone as the sole form of GVHD prophylaxis. Further follow-up is 
needed to determine the effects of CD8 depletion on rates of 
chronic GVHD and relapse. 
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Sleight, Bd; Cl:mT, K.:; Serrmm, A); Gil'ma,, A.; 1. Pediatries, Yale 
U, iversity, New Haven, CT; 2. 3lID Ancterso17 Ca,cer Ce~tte'r, Holts- 
ton, TX; 3. C/:ildreTz's Mercy Hospital, K:msas City, MO. 
Infliximab inhibits TNF% a major mediator of GVHD patho- 
genesis. In this retrospective r view, we analyzed the use, response 
and to,city of infliximab given for 33 episodes of GVHD in 24 
children. Ages ranged from 4 too-18 yrs (median 5y), with 18 sub- 
jects <10 yo. Diagnoses included ALL (I 1), AML (4), SAA (4), and 
1 each with ALD, NHL, Fanconi's anemia, Hurler and Omenn's 
syndrome. Eighteen patients had 25 episodes of aGVHD. Sixteen 
had steroid refractory aGVHD, in addition, 6/18 subjects were 
refractory to ATG (3) +/or daclizumab (4). At initiation of inflix- 
imab, episodes of aGVHD were grade I-Ii (1I) and grade III-IV 
(14). Infli~mab (10 mg/kg) was administered I-3x per week. Dos- 
ing frequency was increased for 2 patients with protein-losing 
enteropathy. In aGVHD patients, 110 total doses were given 
(range 1-58; median 3 doses per flare). Many patients with signifi- 
cant GVt ID or symptoms received infliximab combined with 
other immunosuppressants i cluding: initiation of or an increased 
dose of MP (3), daclizumab (4), ATG (3), plaquenil (2), MMF (2), 
thalidomide (1), fludarabine (1) an d photopheresis (1). Of evalu- 
able patients, improvement was se~n in 15/16 (94%) episodes of 
skin GVHD [CR I3/16 (81%)] and 11/14 (79%) episodes of G1 
GVHD [CR 11/14 (79%)]. One of 3 cases of liver GVHD 
responded. Responses were assessed as the best response within 56 
days after starting infliximab. Only 2 of 18 subjects with aGVHD 
are  surviving. Eight patients had 9 episodes of extensive cGVHD. 
Several patients were treated for an acute flare of cGVHD. The 
majority of patients were receiving steroids, TAC/CsA and 
plaquenil. One patient had recently received 2CDA and 2 started 
daclizumab shortly before infliximab. 426 doses of infliximab 
(10mg/kg) were given (range 5-I62; median 16 doses). Two 
patients received 157 and 162 doses, resp. Five of 8 patients 
improved. Only 3 of 8 subjects with cGVHD are surviving with 
many deaths attributed to cGVHD. Prolonged high-dose inflix- 
imab therapy was well tolerated. No infusion related adverse 
events occurred. Many infectious complications (bacterial, viral, 
fimgal) developed as a result of lnuhi-modality imnmnosuppres- 
sion in these high-risk patients. No cases of mycobacterial infec- 
tions were seen. No increased rate nor predominant type of infec 
tion was noted. Infliximab has activity in children with acute and 
chronic GVHD and warrants prospective analysis. 
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MODULATION OF HOST DENDRITIC CELLS BY EXTRACORPOREAL 
PHOTOPHORESIS IN AN ALLOGENEIC BONE MARROW TRANSPLANT 
CONDITIONING REGIMEN 
C'l:a~, G.; Miller, K.; Foss, F. Tl~'ts-New E,g:land 3,h, dical Ce,te/', 
Bosto,, k/b1. 
We demonstrated that Extracorporeal Photophorcsis (ECP) 
ameliorates chronic graft-versus-host disease (cGVHD) by 
decreasing circulating dendritic cell (DC) number and func- 
tion. To explore whether ECP could prevent GVHD through 
similar mechanisms, we transplanted 56 high-risk patients 
with a reduced intensity conditioning regimen of ECP for 2 
days, pentostatin (8rag/m2 by continuous infusion over 48 hr), 
and 600 cGy of TBI. Seven patients (2F, 5M), median age 59 
(range 32 to 70), with MI)S (n=4), AML (n=l), myelofibrosis 
(n=I), or NHL (n=l), were studied to determine the effects of 
ECP on host DC subsets prior to stem cell infusion and DC 
reconstitution. Flow cytometry used CD1 lc to identify mono 
cytoid DC1 cells and CD123 to identify plasmacytoid DC2 
cells. After the two days of ECP, DCls decreased a median of 
3% (range -39 to +35%), while DC2s decreased a median of 
47% (range -I00 to +51%). Five patients developed full donor 
mononuclear ceil and DC chimerism by day 100 with no 
grade 2-4 acute GVHD.  in this group, DC ls  and DC2s 
decreased in 2 and 4 patients respectively. Of the 2 patients 
who failed to engraft, both had decreases in DC1 and one had 
a decrease in DC2 cells. While our sample size is small, the 
data suggest hat ECP induces similar changes in DC subsets 
in these patients as in our patients with cGVHD. Since the 
overall incidence of grade 2-4 aGVHD in 56 patients was 
10%, these preliminary data suggest hat immunomodulation 
of host DCs by ECP prior to allogeneic stem cell infusion 
may play a role in reducing alloreactivity and thereby attenu- 
ate the incidence and severity of aGVHD. Further studies will 
be needed to determine whether these immunomodulatory 
effects of ECP prior to allogeneic stem cell infusion are corre- 
lated with incidence and severity of GVHD in other condi- 
tioning regimens. 
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DONOR CD8 T-CELL SUPPORT OF HEMATOPOIETIC PROGENITOR 
ACTIVITY DURING SYNGENEIC BMT 
Ha~zash, A.M.; Levy, R.B. Micribiology & Immu,ology, University of 
Miami School of MedMne, Miami, FL. 
Efforts to reduce graft vs. host disease (GVHD) during bone 
marrow transplantation (BMT) by removing donor T-cells from 
96 
